This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Examining the potential of Arvinas' Novel PROTAC Degrader Bavdegalutamide (ARV-110) in prostate cancer
Ticker(s): ARVNWho's the expert?
Institution: UT Southwestern
- Professor of Urology at UT Southwestern Medical Center and treats patients with soft-tissue tumors and kidney, prostate, bladder, testicular, penile, and adrenal cancers
- Currently manages 250-300 patients with prostate cancer.
- Published research in a variety of medical journals and is a fellow of the American College of Surgeons and a member of the Society of Urologic Oncology, Endourologic Society, American Urological Association, American Medical Association, Texas Medical Association, Texas Urologic Association, Dallas County Medical Society, and Harris County Medical Society.
Interview GoalThis conversation will focus on ARVN's PROTAC degrader Bavdegalutamide (ARV-110) in treating prostate cancer. We'll dig into the new data from the Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
